BR112017025851A2 - compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo - Google Patents

compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo

Info

Publication number
BR112017025851A2
BR112017025851A2 BR112017025851-0A BR112017025851A BR112017025851A2 BR 112017025851 A2 BR112017025851 A2 BR 112017025851A2 BR 112017025851 A BR112017025851 A BR 112017025851A BR 112017025851 A2 BR112017025851 A2 BR 112017025851A2
Authority
BR
Brazil
Prior art keywords
methods
disorders
inhibition
treatment
related diseases
Prior art date
Application number
BR112017025851-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Arshad Siddiqui M.
Ciblat Stephane
Dery Martin
Constantineau-Forget Lea
Grand-Maitre Chantal
Guo Xiangyu
Srivastava Sanjay
W. Shipps Gerald
B. Cooper Alan
Bruneau-Latour Nicolas
Linh Ly Vu
Original Assignee
Bantam Pharmaceutical, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical, Llc filed Critical Bantam Pharmaceutical, Llc
Publication of BR112017025851A2 publication Critical patent/BR112017025851A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017025851-0A 2015-06-01 2016-06-01 compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo BR112017025851A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169376P 2015-06-01 2015-06-01
US62/169,376 2015-06-01
PCT/US2016/035288 WO2016196644A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Publications (1)

Publication Number Publication Date
BR112017025851A2 true BR112017025851A2 (pt) 2018-10-16

Family

ID=56118071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025851-0A BR112017025851A2 (pt) 2015-06-01 2016-06-01 compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo

Country Status (9)

Country Link
US (2) US10537558B2 (https=)
EP (1) EP3303332A1 (https=)
JP (1) JP6707630B2 (https=)
CN (1) CN108349962A (https=)
BR (1) BR112017025851A2 (https=)
CA (1) CA3025492A1 (https=)
IL (1) IL255898A (https=)
MX (1) MX2017015456A (https=)
WO (1) WO2016196644A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303332A1 (en) 2015-06-01 2018-04-11 Bantam Pharmaceutical, LLC Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
MX2019006296A (es) * 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
AU2017366901B2 (en) * 2016-11-30 2022-09-29 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
EP3778583B1 (en) 2018-03-30 2025-06-18 Sumitomo Chemical Company, Limited Heterocyclic compound and arthropod pest control composition containing same
WO2019236966A2 (en) 2018-06-07 2019-12-12 Bantam Pharmaceutical, Llc Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
WO2020243582A1 (en) * 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Methods for making thiszolylpyrazole carboxylic acids and intermediates therefor
JP7085697B2 (ja) 2019-11-01 2022-06-16 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
AU2021230289A1 (en) * 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
IT1301968B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
DE60006057T2 (de) * 1999-12-03 2004-05-27 Pfizer Products Inc., Groton Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
US6900219B2 (en) 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1618099A4 (en) 2003-04-18 2008-07-16 Merck & Co Inc BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
US8642597B2 (en) 2007-08-27 2014-02-04 Basf Se Pyrazole compounds for controlling invertebrate pests
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
SI2275414T1 (sl) 2008-04-28 2015-10-30 Kyorin Pharmaceutical Co., Ltd., Ciklopentilakrilamidni derivat
EP2651405A2 (en) * 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US9409901B2 (en) 2012-10-22 2016-08-09 Bantam Pharmaceutical, Llc Compositions and methods for treating or preventing diseases or disorders associated with misregulated EIF4E
JP6434989B2 (ja) 2014-03-27 2018-12-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ピリジルピペリジン
US10125139B2 (en) 2015-04-24 2018-11-13 Syngenta Crop Protection Ag Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles
EP3303332A1 (en) 2015-06-01 2018-04-11 Bantam Pharmaceutical, LLC Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Also Published As

Publication number Publication date
WO2016196644A1 (en) 2016-12-08
EP3303332A1 (en) 2018-04-11
CN108349962A (zh) 2018-07-31
US10537558B2 (en) 2020-01-21
JP2018521119A (ja) 2018-08-02
US20200261424A1 (en) 2020-08-20
JP6707630B2 (ja) 2020-06-10
IL255898A (en) 2018-01-31
US11602526B2 (en) 2023-03-14
CA3025492A1 (en) 2016-12-08
US20180311218A1 (en) 2018-11-01
MX2017015456A (es) 2018-11-29

Similar Documents

Publication Publication Date Title
BR112017025851A2 (pt) compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
MY197635A (en) Benzooxazole derivatives as immunomodulators
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201800367A1 (ru) Способы лечения болезни хантингтона
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX376584B (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
JO3633B1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements